Drug Profile
Dabocemagene autoficel - Fibrocell Science
Alternative Names: D-Fi; FCX-007; Fibroblast epidermolysis bullosa cell therapy -Fibrocell/Intrexon; Fibroblast epidermolysis bullosa dystrophica cell therapy - Fibrocell/Intrexon; Fibroblast epidermolysis bullosa dystrophica gene thearpy - Fibrocell/Intrexon; Fibroblast epidermolysis bullosa gene therapy -Fibrocell/Intrexon; Fibroblast-RDEB-cell-therapy-Fibrocell/Intrexon; Fibroblast-RDEB-gene-therapy-Fibrocell/Intrexon; Genetically modified human dermal fibroblast-collagen VII; Genetically-Modified Autologous Human Dermal Fibroblasts; GM-HDF-COL7Latest Information Update: 12 Dec 2022
Price :
$50
*
At a glance
- Originator Fibrocell Science
- Developer Fibrocell Science; Precigen Inc
- Class Cell therapies; Fibroblast cell therapies; Gene therapies; Skin disorder therapies
- Mechanism of Action Cell replacements; Collagen type VII replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Epidermolysis bullosa dystrophica
Most Recent Events
- 07 Dec 2022 Dabocemagene autoficel is still in phase III trials for Epidermolysis bullosa in USA (NCT04213261)
- 18 Apr 2022 Castle Creek Biosciences terminates phase I trial in Epidermolysis bullosa dystrophica in USA (NCT02810951)
- 25 Jan 2022 Castle Creek Biosciences plans to submit Clinical Trial Application to USA FDA for phase III trial for epidermolysis bullosa dystrophica (Paragon Biosciences pipeline, January 2022) (Castle Creek Biosciences pipeline, January 2022)